APH vs CTNM · P/E 40, rev $23.09B vs $429.6M cap
Amphenol Corporation (APH) versus Contineum Therapeutics, Inc. Class A Common Stock (CTNM) — a side-by-side from cached financials, not a winner call.
Amphenol Corporation (APH) is a electronic components company listed on US.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a biotechnology company listed on US.
Latest reported APH revenue for 2025-12-31 was $23.09B. Net income was $4.27B. Revenue was up 51.7% from 2024-12-31 to 2025-12-31. APH currently screens at market cap $170.77B and trailing P/E 39.9.
Latest reported CTNM revenue for 2024-12-31 was $0. Net income was -$42.3M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. CTNM currently screens at market cap $429.6M.
APH currently screens at market cap $170.77B and trailing P/E 39.9. CTNM currently screens at market cap $429.6M.
Not investment advice. Open the APH and CTNM stock pages for the full models.
Not investment advice.